Top Message

Established in Kagoshima in 1957 as Japan's first contract research organization (CRO),SNBL has built a unique business model centered on life sciences related to drug development with the mission of "supporting the improvement of drug discovery and medical technology and freeing humanity from suffering."

Since its founding, the company has established a solid business foundation in the non-clinical trial contract business, expanded into the clinical trial contract field in 1991, and further established a Translational Research (TR) division in 1997 to develop drug discovery platform technologies, which are the upstream areas of pharmaceutical development. In 2005, the company launched the Medipolis business, which aims to balance and achieve social benefits from the perspectives of ESG/SDGs, in addition to economic benefits.

Currently, as a CRO, we are globally expanding our support business to quickly deliver better pharmaceuticals and medical care to patients across all new drug discovery modalities. Additionally, as part of our TR business, we are actively engaging in new ventures by investing in and providing management support to outstanding biotech ventures that share our vision. Several of these biotech ventures have gone public both domestically and internationally. By collaborating with major pharmaceutical companies and licensing out, these successful biotech ventures have enabled us to build a track record in new drug development support that other CROs cannot achieve.

Under the slogan "I am happy, you are happy, everyone is happy," we are committed to enhancing corporate value. We sincerely ask for the continued support and encouragement of all our stakeholders.

SNBL Co., Ltd.

Chairman and CEO